{"id":3171,"date":"2018-09-12T15:27:02","date_gmt":"2018-09-12T09:57:02","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3171"},"modified":"2021-07-24T12:57:03","modified_gmt":"2021-07-24T07:27:03","slug":"snippet-6","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/snippet-6","title":{"rendered":"Snippet"},"content":{"rendered":"

Aimovig of Amgen commence robust for<\/strong> migraine treatment<\/strong><\/p>\n

The U.S.\u00a0<\/strong>Food and Drug Administration (FDA)<\/strong>\u00a0has given the approval to\u00a0preventative migraine <\/a>treatment, Aimovig<\/strong> of Amgen<\/strong>. Aimovig has a price of USD 6,900<\/strong> per year, but according to analysis of sales, it gives information that migraine treatment is making its way to the front as a preferred treatment. An analysis done by\u00a0Seeking Alpha, IMS data shows that\u00a0new patient are going strong\u00a0for the anti-CGRP treatment. The data showed that 20,000 patients are using the treatment by Seeking Alpha\u00a0analysis. Also 11,000 patients more are anticipated to commence taking the medication for treatment of their migraines. Aimovig is currently being used by patients, who are \u201cboth episodic and chronic migraine <\/a>patients<\/strong>\u201d and is also being taken by patients who \u201care on another suboptimal preventive drug<\/strong>.\u201d The treatment was given approval by the FDA<\/strong> after\u00a0Phase III<\/strong> results\u00a0indicated the medication decreased monthly migraine attacks to half. The medication is the only FDA-accepted treatment specifically developed to avert migraine by hindering the calcitonin gene-related peptide receptor (CGRP-R). As Amgen likes paving the way in migraine research, the company can also enter in the multiple myeloma market. Amgen released data from its pipeline drug AMG-420, bispecific T cell engager, got acquisition from Boehringer Ingelheim. Data showed five patients treated with AMG-420 indicated strict complete responses in relapsed\/refractory multiple myeloma, according to Seeking Alpha. AMG-420 aims B-cell maturation antigen (BCMA), a target in multiple myeloma<\/a>, due to its constrained expression of normal tissue and uniform expression on multiple myeloma cells.\u00a0 When acquired the treatment from BI, Amgen observed that the modified antibodies from the therapeutics are designed to involve two different targets simultaneously, thus juxtaposing T cells (a type of white blood cell capable of killing other cells that are seemed as threats) to cancer cells. The drug has a long way to go before receiving regulatory approval, and it could become a principal treatment in the multiple myeloma space.<\/p>\n

\n","protected":false},"excerpt":{"rendered":"

Aimovig of Amgen commence robust for migraine treatment The U.S.\u00a0Food and Drug Administration (FDA)\u00a0has given the approval to\u00a0preventative migraine treatment, Aimovig of Amgen. Aimovig has a price of USD 6,900 per year, but according to analysis of sales, it gives information that migraine treatment is making its way to the front as a preferred treatment. […]<\/p>\n","protected":false},"author":1,"featured_media":3173,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[1798,1801,831,1800,1799,704,474,1786],"industry":[17225],"therapeutic_areas":[17245,17228,17234],"class_list":["post-3171","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-aimovig","tag-amg-420","tag-amgen","tag-chronic-migraine-patients","tag-episodic-migraine-patients","tag-fda","tag-phase-iii","tag-u-s-food-and-drug-administration-fda","industry-pharmaceutical","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"\nSnippet 12\/09\/2018 - DelveInsight Business Research LLP<\/title>\n<meta name=\"description\" content=\"The U.S.\u00a0Food and Drug Administration (FDA)\u00a0has given the approval to\u00a0preventative migraine treatment, Aimovig of Amgen. Aimovig has a....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/snippet-6\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snippet 12\/09\/2018 - DelveInsight Business Research LLP\" \/>\n<meta property=\"og:description\" content=\"The U.S.\u00a0Food and Drug Administration (FDA)\u00a0has given the approval to\u00a0preventative migraine treatment, Aimovig of Amgen. Aimovig has a....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/snippet-6\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-12T09:57:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09164122\/Diagnosis-Migraine-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"825\" \/>\n\t<meta property=\"og:image:height\" content=\"550\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Snippet 12\/09\/2018 - DelveInsight Business Research LLP","description":"The U.S.\u00a0Food and Drug Administration (FDA)\u00a0has given the approval to\u00a0preventative migraine treatment, Aimovig of Amgen. Aimovig has a....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/snippet-6","og_locale":"en_US","og_type":"article","og_title":"Snippet 12\/09\/2018 - DelveInsight Business Research LLP","og_description":"The U.S.\u00a0Food and Drug Administration (FDA)\u00a0has given the approval to\u00a0preventative migraine treatment, Aimovig of Amgen. Aimovig has a....","og_url":"https:\/\/www.delveinsight.com\/blog\/snippet-6","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-09-12T09:57:02+00:00","article_modified_time":"2021-07-24T07:27:03+00:00","og_image":[{"width":825,"height":550,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09164122\/Diagnosis-Migraine-1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-6","url":"https:\/\/www.delveinsight.com\/blog\/snippet-6","name":"Snippet 12\/09\/2018 - DelveInsight Business Research LLP","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-6#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-6#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09164122\/Diagnosis-Migraine-1.jpg","datePublished":"2018-09-12T09:57:02+00:00","dateModified":"2021-07-24T07:27:03+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The U.S.\u00a0Food and Drug Administration (FDA)\u00a0has given the approval to\u00a0preventative migraine treatment, Aimovig of Amgen. Aimovig has a....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/snippet-6"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-6#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09164122\/Diagnosis-Migraine-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09164122\/Diagnosis-Migraine-1.jpg","width":825,"height":550,"caption":"Migraine"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09164122\/Diagnosis-Migraine-1-300x200.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Aimovig<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">AMG-420<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Amgen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">chronic migraine patients<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">episodic migraine patients<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Phase III<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">U.S. Food and Drug Administration (FDA)<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Aimovig<\/span>","<span class=\"advgb-post-tax-term\">AMG-420<\/span>","<span class=\"advgb-post-tax-term\">Amgen<\/span>","<span class=\"advgb-post-tax-term\">chronic migraine patients<\/span>","<span class=\"advgb-post-tax-term\">episodic migraine patients<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Phase III<\/span>","<span class=\"advgb-post-tax-term\">U.S. Food and Drug Administration (FDA)<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 12, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 12, 2018 3:27 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3171"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3171\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3173"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3171"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3171"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}